Company news
Argenica Therapeutics Ltd (ASX:AGN) news
Argenica Therapeutics Ltd news releases on 6ix. Latest, Aug 18, 2023: Response to ASX Aware Query
Press releases — page 2
Response to ASX Aware Query
August 18, 2023
ARG-007 Prevents Uptake & Aggregation of Key Protein
July 31, 2023
Investor Presentation
July 24, 2023
ARG-007 Phase 2 Clinical Trial Update
July 18, 2023
ARG-007 Protects Brain Cells in Moderate TBI Model
June 21, 2023
Argenica Successfully Completes $4.0m Placement
June 1, 2023
Final Phase1 Clinical Trial Report
May 14, 2023
Latest Preclinical HIE Study Results
April 19, 2023
Significant Non-Dilutive Funding For Preclinical HIE Studies
March 29, 2023
Interim Phase 1 Safety Report Confirms Safety of ARG-007
March 5, 2023
Non-Dilutive Funding Received to Progress Alzheimers Studies
February 21, 2023
Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
February 8, 2023
Argenica Awarded $1.2m CRC-P Grant for TBI Project
January 19, 2023
Successful Completion of Phase 1 Clinical Trial Dosing
December 20, 2022
SRC Approves Commencement Of Fourth And Final Cohort Dosing
December 7, 2022
Phase 1 Clinical Trial Progress Update
November 24, 2022
Safety Review Committee Approves Third Cohort Commencement
November 17, 2022
Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial
November 6, 2022
Safety Review Committee Approves Second Cohort
November 1, 2022
No Serious Safety Issues Observed in First Cohort
October 25, 2022
First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007
October 16, 2022
Argenica Receives $1.38m R&D Tax Incentive Cash Refund
October 3, 2022
Further Positive Preclinical Results for ARG-007 In HIE
September 28, 2022
Argenica Receives Ethics Approval To Commence Phase 1 Trial
September 6, 2022
Appendix 4E & Annual Report 30 June 2022
August 23, 2022
Peer Reviewed Paper Published on Preclinical Safety Study
July 6, 2022
Argenica Therapeutics : Application for quotation of securities - AGN
June 9, 2022
Argenica Successfully Completes $5.5m Placement
June 3, 2022
Argenica Therapeutics : Proposed issue of securities - AGN
June 2, 2022
Successful Completion of Final Pre-Clinical PK Study
May 18, 2022
GLP Safety Studies Successfully Completed
May 4, 2022
Maximum Tolerated Dose Successfully Established in Studies
April 25, 2022
Argenica Appoints CEO Dr Liz Dallimore Managing Director
April 3, 2022
Positive Preclincal Data on Efficacy in New Indication
March 29, 2022
Peer Reviewed Paper Published on Preclinical Study
March 20, 2022
Successful Completion of Final GLP Genotoxicity Studies
February 23, 2022
Preliminary Pre-Clinical Tox Studies Successfully Completed
January 23, 2022
Argenica to be Granted Patent Protection in the US
December 8, 2021
Positive Preclinical Data for ARG-007 Neuroprotection in HIE
November 2, 2021
Phase 1 Clinical Trial Overview & Roadmap
October 17, 2021
Argenica Partners With Linear For Phase 1 Clinical Trial
September 30, 2021
Argenica Achieves Manufacturing Milestones
September 13, 2021
Appendix 4E & Annual Report 30 June 2021
August 26, 2021
Grant Secured to Advance Pre-Clinical Studies Of ARG-007
July 20, 2021
Study Additional Information
July 13, 2021
Study Shows ARG-007 Does Not Degrade
July 12, 2021
Argenica Completes Pilot Pre-Clinical Pharmacokinetics Study
July 1, 2021